Clinical Trial Update: Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in relapsed or refractory diffuse large B-cell lymphoma; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Revlimid (lenalidomide)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-05